Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

V. Domenyuk, X. Liu, D. Magee, Z. Gatalica, A. Stark, P. Kennedy, M. Rosenow, A. Barker, D. Berry, G. Poste, D. Halbert, C. Hart, M. Famulok, G. Mayer, M. Korn, M. Miglarese, D. Spetzler

Research output: Contribution to journalArticle

56 Scopus citations
Original languageEnglish (US)
Pages (from-to)v36
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Jun 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Domenyuk, V., Liu, X., Magee, D., Gatalica, Z., Stark, A., Kennedy, P., Rosenow, M., Barker, A., Berry, D., Poste, G., Halbert, D., Hart, C., Famulok, M., Mayer, G., Korn, M., Miglarese, M., & Spetzler, D. (2018). Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v36. https://doi.org/10.1093/annonc/mdy151.131